Home › Research › How common it is
Study of Ancestry, Health, Environment, and Late-Life Neurodegeneration (SAHEL)
Kwairanga, S. H.; Iwar, H. J.; Faruk, A. U.; Wakawa, I. A.; Musami, U. B.; Ogualili, P. N.; Mahmood, M. Y.; Fugu et al.. medRxiv (preprint), 2026-09-24
Topic: Risk, prevention and care in population studies
Plain-language summary
INTRODUCTIONDementia research in sub-Saharan Africa remains limited despite rapid population aging and substantial ancestral, environmental, and vascular diversity. The Study of Ancestry, Health, Environment, and Late-Life Neurodegeneration (SAHEL) characterizes late-life cognitive decline and neurodegeneration in north-eastern Nigeria. METHODSSAHEL comprises community and hospital cohorts of adults aged 55 years or older in Yobe and Borno States. Participants undergo cognitive, functional, environmental, cardiovascular, metabolic, neuropsychiatric, and neurological assessments. Blood is collected for clinical profiling and biobanking, and consenting hospital participants provide skin biopsies for induced pluripotent stem cell generation. Planned analyses will integrate gut microbiota profiling, retinal imaging, and brain magnetic resonance imaging to investigate biological pathways and markers associated with healthy aging and cognitive outcomes. RESULTSFrom August 2025 through February 2026, 1,044 community participants were screened (mean age, 69.4 years; 56.4% female); 379 (36.3%) screened positive for cognitive concern and entered longitudinal follow-up. The hospital cohort enrolled 102 participants (mean age, 73.5 years; 57.8% male), including participants with Alzheimers disease, vascular dementia, mixed dementia, and mild cognitive impairment. Blood was collected from 809 community participants and all hospital participants. The cohort includes Kanuri, Fulani, Hausa, Babur/Bura, and Shuwa Arab participants. DISCUSSIONSAHEL has established a large, deeply characterized aging and dementia research platform in north-eastern Nigeria. Its linked clinical, environmental, biomarker, genomic, imaging, microbiome, and cellular resources will enable investigation of population-specific risk and resilience mechanisms and strengthen dementia research and precision medicine in African populations.
What this study adds
Evidence grade: Moderate
This is a follow-up (cohort) study of 102 participants. This describes a new long-term study in north-eastern Nigeria that will follow older adults to understand cognitive decline and neurodegeneration in a region where such research is limited. Reported effect size: 56.4%; 36.3%; 57.8%.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Kwairanga, S. H., Iwar, H. J., Faruk, A. U., Wakawa, I. A., Musami, U. B., Ogualili, P. N., et al. (2026). Study of Ancestry, Health, Environment, and Late-Life Neurodegeneration (SAHEL). medRxiv (preprint). https://doi.org/10.64898/2026.09.23.26363703
Vancouver
Kwairanga SH, Iwar HJ, Faruk AU, Wakawa IA, Musami UB, Ogualili PN, et al. Study of Ancestry, Health, Environment, and Late-Life Neurodegeneration (SAHEL). medRxiv (preprint). 2026. doi:10.64898/2026.09.23.26363703.
BibTeX
@article{kwairanga2026-8612faa3,
author = {Kwairanga, S. H. and Iwar, H. J. and Faruk, A. U. and Wakawa, I. A. and Musami, U. B. and Ogualili, P. N. and Mahmood, M. Y. and Fugu and others},
title = {{Study of Ancestry, Health, Environment, and Late-Life Neurodegeneration (SAHEL)}},
journal = {medRxiv (preprint)},
year = {2026},
doi = {10.64898/2026.09.23.26363703},
url = {https://doi.org/10.64898/2026.09.23.26363703}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Planned analyses will integrate gut microbiota profiling, retinal imaging, and brain magnetic resonance imaging to investigate biological pathways and markers associated with healthy aging and cognitive outcomes.
Why it matters
This describes a new long-term study in north-eastern Nigeria that will follow older adults to understand cognitive decline and neurodegeneration in a region where such research is limited. It has enrolled participants and collected samples, but no results on treating, curing, or preventing Alzheimer's are available yet.
New to this subject? Start with our plain-English guide: Alzheimer's in numbers →
Study details
- Study designlongitudinal study
- Participants102
- Effect size56.4%; 36.3%; 57.8%
- Evidence strengthModerate
How this study scored 16/100
Preprint — not yet peer-reviewed. It scored 39 on the same rubric, but non-peer-reviewed sources are capped at 16, so it shows as 16. Scored zero for randomized / blinded because the record does not state it. We have no data on impact for its field and year, so that was left out: it earned 37 of the 94 points we could judge it on, which is 39 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 2 / 10 | Tier 4 — not a peer-reviewed journal (medRxiv (preprint)) |
| Journal's citation record | 0 / 4 | Not a journal article, so the journal's record does not count |
| Study design | 7 / 12 | A longitudinal study following the same people over time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 4 / 10 | Preprint — not yet peer-reviewed. Hosted on a preprint server. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 2 / 4 | 102 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 0 / 7 | Cited 0 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.0 citations a year over 2 year(s) since 2026 |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 1 / 4 | Last-listed author Mahmoud Bukar Maina: h-index 16 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | Johns Hopkins University: institution h-index 2,306 (OpenAlex) |
| Multicenter collaboration | 3 / 3 | OpenAlex lists 20 institution(s) in 7 countries |
| Indexed in PubMed | 1 / 2 | Not in PubMed, but has a DOI |
| Free to read | 2 / 2 | Free to read |
| Points | 37 / 94 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 37 of the 94 points we could judge it on is 39 out of 100. |
| Total | 39 / 100 | Capped to 16 because this is not a peer-reviewed article. |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in How common it is from nearby years
Also in How common it is
80 studies in the library are filed under How common it is with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The How common it is hub.